These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35353428)

  • 21. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
    Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features.
    Coura BP; Bernardes VF; de Sousa SF; França JA; Pereira NB; Pontes HAR; Batista AC; da Cruz Perez DE; Albuquerque Junior RLC; de Souza LB; Martins MD; Diniz MG; Gomez RS; Gomes CC
    Mod Pathol; 2019 Jun; 32(6):799-806. PubMed ID: 30643167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
    Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
    Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst.
    Cha YH; Cho ES; Kang HE; Ko J; Nam W; Kim HJ; Kim NH; Kim HS; Cha IH; Yook JI
    Oral Oncol; 2017 Nov; 74():62-67. PubMed ID: 29103753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
    Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenoid ameloblastoma harbors beta-catenin mutations.
    Bastos VC; Coura BP; Guimarães LM; Fernandes BG; Chan AC; Vargas PA; Bastos-Rodrigues L; De Marco LA; Hellstein J; Thavaraj S; Wright JM; Odell EW; Gomez RS; Gomes CC
    Mod Pathol; 2022 Nov; 35(11):1562-1569. PubMed ID: 35840721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
    Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
    J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
    González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R
    World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
    do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
    Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
    Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
    J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An immunohistochemical and genetic study of BRAF
    Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
    Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
    Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
    Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
    Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
    Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
    Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of BRAF p.V600E and Detection Methods in Benign Mixed and Malignant Odontogenic Tumors: A Systematic Review.
    Severino-Lazo RJG; de Vasconcelos Carvalho M; Campello CP; Moraes SLD; do Egito Vasconcelos BC; Pellizzer EP
    Head Neck Pathol; 2023 Dec; 17(4):1000-1010. PubMed ID: 38057461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review.
    Malakar A; Kumar VR; Yadav P; Bhardwaj V; Barua CG; Bhardwaj G
    Cureus; 2023 Oct; 15(10):e47682. PubMed ID: 38021761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.
    Potocki PM; Wójcik P; Chmura Ł; Goc B; Fedewicz M; Bielańska Z; Swadźba J; Konopka K; Kwinta Ł; Wysocki PJ
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.